NEW DELHI: The orthopaedic implant manufacturers have came together to make their representation against the analysis of trade margins earned by companies, hospitals and distributors on knee implants, made by the drug regulator recently.Setting the stage for capping prices of knee implants, National Pharmaceutical Pricing Authority (NPPA) had issued an office memorandum last week with an a detailed analysis showing importers, distributors and hospitals are earning hefty trade margins that can range from 67% to as high as 449%. "We have discussed the issued with NPPA Chairman. Revision knee replacement is usually conducted if the primary knee replacement fails.The latest analysis shows the trade margins even on total revision knee implants are in the range of 56%- 369%. While the total margin varies between 182% to 369%, hospitals and distributors are seen earning the biggest share between 89% to 200%. The trade margin earned by companies fall in the range of 33% to 65%, according the NPPA analysis.However, manufacturers maintain there are "multiple discrepancies in the price points".

Source: Times of India August 09, 2017 16:20 UTC